Who Should Not Take Fadogia Agrestis
Fadogia agrestis, a shrub from West Africa, became one of the most talked-about "natural testosterone boosters" after it was mentioned on popular podcasts. Demand soared far faster than the research. Our editorial team reviewed the available evidence to explain why many people should not take it at all, and why everyone else should think twice.
What Fadogia agrestis is
Fadogia agrestis is a plant in the coffee family (Rubiaceae) traditionally used in Nigerian folk medicine as an aphrodisiac and for erectile problems. Its stem extracts contain alkaloids, saponins, flavonoids and other compounds whose roles are not fully understood.
Supplement interest is based mainly on research from a single Nigerian group in the mid-2000s. In male rats, aqueous stem extracts increased testosterone levels and sexual behavior compared with controls.
These studies have never been replicated in properly designed human clinical trials. As of today, there is no published randomized controlled trial demonstrating that Fadogia agrestis raises testosterone or improves performance in humans.
In the US, Fadogia is sold as a dietary supplement, meaning manufacturers do not have to prove safety or effectiveness before marketing. The FDA can act only after problems are reported.
What the animal studies found about safety
The same research program that reported increased testosterone also raised safety signals. In a 2005 study by Yakubu and colleagues, rats given the extract showed changes suggestive of testicular toxicity, including alterations in enzymes associated with testicular function.
Other rat studies reported changes in liver and kidney function markers at higher doses. Animal findings do not translate directly to humans, but they are a reason for caution, not reassurance.
Animal doses also do not map neatly onto human capsules. Human-equivalent dose conversions are imprecise, and commercial products vary in extract type and strength.
The key takeaway: the same evidence base that is used to sell Fadogia also contains warning signals, and no human data exist to settle the question.
Groups who should avoid it
Given the absence of human safety data and the presence of animal toxicity signals, our editors consider the following groups should not take Fadogia agrestis:
- Men trying to conceive. The testicular toxicity signals in rats are a specific concern for fertility.
- Teenagers and young adults under 21. Their hormonal systems are still developing, and there is no reason to experiment with unstudied hormone-modulating herbs.
- Women, especially during pregnancy and breastfeeding. There are no data, and androgenic effects would be undesirable.
- People with liver or kidney disease. Animal studies reported changes in organ markers.
- Men with hormone-sensitive conditions such as prostate cancer or significant benign prostatic hyperplasia.
- Anyone on testosterone therapy or other hormone treatments, unless explicitly cleared by their physician.
People taking multiple prescription medications should also avoid it, because potential herb-drug interactions have not been studied.
If you have symptoms that make you think about testosterone, such as low libido, fatigue or reduced muscle mass, these deserve a medical evaluation rather than self-treatment.
Risks even for healthy adults
Healthy adult men are the main target market for Fadogia. Even in this group, several risks remain.
A solid starting point is sarm rendelés.
| Concern | Basis | Practical implication |
|---|---|---|
| Testicular effects | Rat studies | Unknown in humans; fertility could be at risk |
| Liver and kidney markers | Rat studies at higher doses | Blood tests advisable if used |
| Product quality | Unregulated extracts | Content may vary or be contaminated |
| Long-term effects | No data | Cannot be assessed |
| Anti-doping | Contamination risk in booster category | Use only certified products if tested |
Popular protocols online often recommend cycling Fadogia on and off to "protect the testicles." This advice acknowledges the risk without having human data to show that cycling actually prevents harm.
Testosterone-booster supplements as a category are known for contamination with undeclared substances. The FDA has issued warnings about products in this category that contained prohibited anabolic agents.
Fadogia itself is not named on the WADA Prohibited List, but competitive athletes face real risk from contaminated booster products.
Safer alternatives and next steps
If your goal is to support healthy testosterone levels, the strongest evidence points to lifestyle factors:
- Sleep 7–9 hours per night; sleep restriction lowers testosterone.
- Maintain a healthy body weight; obesity is strongly associated with low testosterone.
- Do regular resistance training.
- Correct deficiencies in vitamin D and zinc if testing shows them.
- Limit alcohol.
If symptoms persist, ask your physician for morning testosterone testing. The Endocrine Society recommends confirming low levels with repeat tests before any diagnosis.
Medical treatments for confirmed hypogonadism exist and are monitored by physicians, which is very different from experimenting with an unstudied herb.
Editorial team conclusions
Fadogia agrestis has no human clinical trials supporting its effectiveness and animal studies showing possible toxicity. That combination makes it a poor choice for most people.
Men trying to conceive, adolescents, women, people with liver or kidney disease and those with hormone-sensitive conditions should avoid it.
Even healthy adults are taking an unquantified risk. Lifestyle changes and medical evaluation remain the evidence-based route.
See also our articles on tongkat ali research, how to interpret testosterone blood tests, and the risks of testosterone booster contamination.
References
- Yakubu MT, Akanji MA, Oladiji AT. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian J Androl. 2005;7(4):399–404.
- Yakubu MT, Akanji MA, Oladiji AT. Effects of oral administration of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem on some testicular function indices of male rats. J Ethnopharmacol. 2008;115(2):288–292.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173–2174.
- Clemesha CG, Thaker H, Samplaski MK. 'Testosterone boosting' supplements composition and claims are not supported by the academic literature. World J Mens Health. 2020;38(1):115–122.
